Business Standard

Friday, December 27, 2024 | 12:10 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Aspirin may lower risk of ovarian cancer

Image

ANI Washington D.C. [USA]

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer, according to a new study.

Co-led by Moffitt Cancer Center, the study found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to no aspirin users. It was also found that women who were heavy users of no aspirin no steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil) or naproxen (Aleve), over a long period of time had a higher risk of developing ovarian cancer.

Ovarian cancer is the most fatal gynecological cancer, largely due to lack of early detection strategies. It is believed that inflammation that occurs during ovulation plays a role in the development of this cancer. But anti-inflammatory medications, such as aspirin, have been shown to lower the risk of certain types of cancers.

 

For this study, Shelley Tworoger, worked with researchers at Huntsman Cancer Institute and the Harvard T.H. Chan School of Public Health to analyze data from more than 200,000 women who took part in the Nurses' Health Studies based at Brigham and Women's Hospital in Boston.

Of the participants, 1,054 developed ovarian cancer. Researchers looked at the participants' use of aspirin (325 milligrams), low-dose aspirin (100 milligrams or less), non-aspirin NSAIDs and acetaminophen.

Their analysis found that low-dose aspirin use was associated with a lower risk of ovarian cancer while standard-dose aspirin use was not. Conversely, the data showed that women who took non-aspirin NSAIDs often, defined by at least 10 tablets per week for many years, had an increased risk of developing the disease.

"We're not quite at the stage where we could make the recommendation that daily aspirin use lowers ovarian cancer risk. We need to do more research. But it is definitely something women should discuss with their physician," said Tworoger.

The study is present in the journal- JAMA Oncology.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 05 2018 | 6:20 AM IST

Explore News